P
Patricia Kropf
Researcher at Fox Chase Cancer Center
Publications - 46
Citations - 2287
Patricia Kropf is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Regimen. The author has an hindex of 17, co-authored 43 publications receiving 1653 citations. Previous affiliations of Patricia Kropf include Temple University & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner,Cristina E. Tognon,Cristina E. Tognon,Daniel Bottomly,Beth Wilmot,Stephen E. Kurtz,Samantha L. Savage,Nicola Long,Anna Reister Schultz,Elie Traer,Melissa L. Abel,Anupriya Agarwal,Aurora Blucher,Uma Borate,Jade Bryant,Russell T. Burke,Amy S. Carlos,Richie Carpenter,Joseph Carroll,Bill H. Chang,Cody Coblentz,Amanda d’Almeida,Rachel J. Cook,Alexey V. Danilov,Kim Hien T. Dao,Michie Degnin,Deirdre Devine,James Dibb,David K. Edwards,Christopher A. Eide,Christopher A. Eide,Isabel English,Jason M. Glover,Rachel Henson,Hibery Ho,Abdusebur Jemal,Kara Johnson,Ryan C. Johnson,Brian Junio,Andy Kaempf,Jessica Leonard,Chenwei Lin,Selina Qiuying Liu,Pierrette Lo,Marc M. Loriaux,Samuel B. Luty,Tara A. Macey,Jason D. MacManiman,Jacqueline Martinez,Motomi Mori,Dylan Nelson,Ceilidh Nichols,Jill Peters,Justin Ramsdill,Angela Rofelty,Robert Schuff,Robert P. Searles,Erik Segerdell,Rebecca Smith,Stephen E. Spurgeon,Tyler Sweeney,Aashis Thapa,Corinne Visser,Jake Wagner,Kevin Watanabe-Smith,Kristen Werth,Joelle Wolf,Libbey White,Amy Yates,Haijiao Zhang,Christopher R. Cogle,Robert H. Collins,Denise C. Connolly,Michael W. Deininger,Leylah Drusbosky,Christopher S. Hourigan,Craig T. Jordan,Patricia Kropf,Tara L. Lin,Micaela E. Martinez,Bruno C. Medeiros,Rachel R. Pallapati,Daniel A. Pollyea,Ronan T. Swords,Justin M. Watts,Scott Weir,David L. Wiest,Ryan M. Winters,Shannon K. McWeeney,Brian J. Druker,Brian J. Druker +90 more
TL;DR: Analyses of samples from patients with acute myeloid leukaemia reveal that drug response is associated with mutational status and gene expression; the generated dataset provides a basis for future clinical and functional studies of this disease.
Journal ArticleDOI
Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology
Margaret R. O'Donnell,Martin S. Tallman,Camille N. Abboud,Jessica K. Altman,Frederick R. Appelbaum,Daniel A. Arber,Vijaya Raj Bhatt,Dale L. Bixby,William Blum,Steven Coutre,Marcos de Lima,Amir T. Fathi,Melanie Fiorella,James M. Foran,Steven D. Gore,Aric C. Hall,Patricia Kropf,Jeffrey E. Lancet,Lori J. Maness,Guido Marcucci,Michael Gary Martin,Joseph O. Moore,Rebecca L. Olin,Deniz Peker,Daniel A. Pollyea,Keith W. Pratz,Farhad Ravandi,Paul J. Shami,Richard Stone,Stephen A. Strickland,Eunice S. Wang,Matthew J. Wieduwilt,Kristina M. Gregory,Ndiya Ogba +33 more
TL;DR: This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger and older adult patients.
Journal ArticleDOI
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Hagop M. Kantarjian,Gail J. Roboz,Patricia Kropf,Karen W.L. Yee,Casey O'Connell,Raoul Tibes,Katherine Walsh,Nikolai A. Podoltsev,Elizabeth A. Griffiths,Elias Jabbour,Guillermo Garcia-Manero,David A. Rizzieri,Wendy Stock,Michael R. Savona,Todd L. Rosenblat,Jesus G. Berdeja,Farhad Ravandi,Edwin P. Rock,Yong Hao,Mohammad Azab,Jean Pierre J. Issa +20 more
TL;DR: This phase 2 study aimed to assess the safety and activity of two doses and schedules of guadecitabine in older (≥65 years) patients with treatment-naive acute myeloid leukaemia who were not candidates for intensive chemotherapy.
Journal ArticleDOI
DNA Hypomethylating Drugs in Cancer Therapy.
TL;DR: Preclinical and clinical data on DNA hypomethylating drugs as a cancer therapy are summarized and a next-generation drug (guadecitabine) is currently in clinical trials.
Journal ArticleDOI
Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines
Susan O'Brien,Jerald P. Radich,Camille N. Abboud,Mojtaba Akhtari,Jessica K. Altman,Ellin Berman,Daniel J. DeAngelo,Michael W. Deininger,Steven M. Devine,Amir T. Fathi,Jason Gotlib,Madan Jagasia,Patricia Kropf,Joseph O. Moore,Arnel Pallera,Javier Pinilla-Ibarz,Vishnu Reddy,Neil P. Shah,B. Douglas Smith,David S. Snyder,Meir Wetzler,Kristina M. Gregory,Hema Sundar +22 more
TL;DR: The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy.